• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

推荐意见:应对慢性髓性白血病临床试验中除总生存期以外终点所带来的统计学挑战。

Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia.

机构信息

Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie-IBE, Ludwig-Maximilians-Universität, München, Germany.

出版信息

Leukemia. 2011 Sep;25(9):1433-8. doi: 10.1038/leu.2011.116. Epub 2011 May 20.

DOI:10.1038/leu.2011.116
PMID:21597465
Abstract

The aim of this work was to provide guidelines for appropriate statistical analyses regarding most common endpoints in clinical trials on chronic myeloid leukemia: hematologic, cytogenetic and molecular results, failure-free and event-free survival, and progression-free and overall survival. The reasons for the specified recommendations are explained and important issues are outlined by comprehensive examples. Particular attention is paid to the warning of the application of suboptimal methods that may lead to seriously biased results and conclusions. In the presence of a competing risk like death, Kaplan-Meier analysis should not be applied for time-to-remission endpoints. The appropriate method to estimate the probabilities of a time-to-remission endpoint is the calculation of its cumulative incidence function. However, the exact date of remission is hardly known. Detection of remission depends strongly on evaluation frequencies. Complex composite endpoints comprising many events with considerably heterogeneous severity imply difficulties with interpretation. Time-to-remission and complex composite endpoints are not recommended for primary judgment on efficacy. It is rather advisable to investigate remission status at a fixed time point as a primary endpoint, followed by progression-free and overall survival. For patients with the intended remission success at the time point of interest, relapse-free survival provides an additional primary outcome.

摘要

本研究旨在为慢性髓性白血病临床试验中最常见的终点(血液学、细胞遗传学和分子学结果、无失败和无事件生存、无进展和总生存)的适当统计分析提供指导。指定建议的原因得到了解释,并通过综合示例概述了重要问题。特别注意警告应用可能导致严重偏倚结果和结论的次优方法。在存在死亡等竞争风险的情况下,不应应用 Kaplan-Meier 分析来评估缓解时间终点。估计缓解时间终点概率的适当方法是计算其累积发生率函数。然而,缓解的确切日期很难得知。缓解的检测在很大程度上取决于评估频率。包含许多严重程度差异较大的事件的复杂复合终点意味着解释困难。缓解时间和复杂的复合终点不推荐作为疗效的主要判断依据。更明智的做法是在固定时间点作为主要终点研究缓解状态,然后研究无进展和总生存。对于在关注时间点有预期缓解成功的患者,无复发生存提供了另一个主要结果。

相似文献

1
Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia.推荐意见:应对慢性髓性白血病临床试验中除总生存期以外终点所带来的统计学挑战。
Leukemia. 2011 Sep;25(9):1433-8. doi: 10.1038/leu.2011.116. Epub 2011 May 20.
2
Competing time-to-event endpoints in cardiology trials: a simulation study to illustrate the importance of an adequate statistical analysis.心脏病学试验中相互竞争的事件发生时间终点:一项模拟研究以说明充分统计分析的重要性。
Eur J Prev Cardiol. 2014 Jan;21(1):74-80. doi: 10.1177/2047487312460518. Epub 2012 Sep 10.
3
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.在接受伊马替尼治疗的慢性髓性白血病患者中,在获得完全细胞遗传学缓解(CCgR)时达到主要分子学缓解预示着CCgR的持续时间更长。
Clin Cancer Res. 2006 May 15;12(10):3037-42. doi: 10.1158/1078-0432.CCR-05-2574.
4
Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications.在存在竞争风险的情况下评估健康结局:统计方法和临床应用的综述。
Med Care. 2010 Jun;48(6 Suppl):S96-105. doi: 10.1097/MLR.0b013e3181d99107.
5
[Allogeneic bone marrow transplantation in chronic myeloid leukemia. The clinical results and risk factors in 70 patients].[慢性粒细胞白血病的异基因骨髓移植。70例患者的临床结果及危险因素]
Med Clin (Barc). 1995 Nov 11;105(16):605-11.
6
Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.癌症临床试验中评估时间事件终点的定义方案(DATECAN)项目:为癌症临床试验中标准化时间事件终点定义制定指南的正式共识方法。
Eur J Cancer. 2013 Mar;49(4):769-81. doi: 10.1016/j.ejca.2012.09.035. Epub 2012 Nov 2.
7
Interpretation of clinical endpoints in trials of acute myeloid leukemia.急性髓系白血病试验中临床终点的解读
Leuk Res. 2018 May;68:32-39. doi: 10.1016/j.leukres.2018.02.002. Epub 2018 Feb 7.
8
Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy.慢性髓性白血病患者的预后及预后因素:非移植治疗
Semin Hematol. 2003 Jan;40(1):4-12. doi: 10.1053/shem.2003.50006.
9
Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors: the Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Español de Trasplante Hemopoyético).异基因干细胞移植后慢性髓性白血病的复发:结局与预后因素:西班牙造血移植组(GETH)慢性髓性白血病小组委员会
Bone Marrow Transplant. 2005 Aug;36(4):301-6. doi: 10.1038/sj.bmt.1705063.
10
[Effectiveness of allogeneic bone marrow transplantation in patients with acute leukemia in complete remission and in patients with chronic myeloid leukemia during the chronic phase].
Ter Arkh. 1999;71(7):27-32.

引用本文的文献

1
Prognostic scoring systems in chronic myeloid leukaemia.慢性髓性白血病的预后评分系统
Leukemia. 2025 May;39(5):1046-1052. doi: 10.1038/s41375-025-02606-6. Epub 2025 Apr 15.
2
Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia.慢性髓性白血病中 BCR::ABL1 e14a2 和 e13a2 转录本的分子反应和结果比较。
Cancer Sci. 2022 Oct;113(10):3518-3527. doi: 10.1111/cas.15501. Epub 2022 Aug 17.
3
Initial Rate of Decline for Response Prediction in Chronic Myeloid Leukemia.
慢性髓性白血病反应预测的初始下降率
Turk J Haematol. 2022 Aug 25;39(3):204-205. doi: 10.4274/tjh.galenos.2022.2022.0247. Epub 2022 Jun 14.
4
and germ line variants predict response and identify CML patients with the greatest risk of imatinib failure.并且种系变异可预测反应并识别出伊马替尼治疗失败风险最高的慢性粒细胞白血病患者。
Blood Adv. 2017 Jul 31;1(18):1369-1381. doi: 10.1182/bloodadvances.2017006825. eCollection 2017 Aug 8.
5
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.伊马替尼作为慢性粒细胞白血病一线治疗的评估:随机CML研究IV的10年生存结果及非CML决定因素的影响
Leukemia. 2017 Nov;31(11):2398-2406. doi: 10.1038/leu.2017.253. Epub 2017 Aug 14.
6
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.尼洛替尼每日两次,每次300毫克:一项针对新诊断的慢性期慢性髓性白血病患者的单臂学术研究。
Haematologica. 2016 Oct;101(10):1200-1207. doi: 10.3324/haematol.2016.144949. Epub 2016 Jul 28.
7
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.考虑到慢性髓性白血病患者的疾病特异性死亡,长期生存的预后。
Leukemia. 2016 Jan;30(1):48-56. doi: 10.1038/leu.2015.261. Epub 2015 Sep 29.
8
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.伊马替尼一线治疗慢性髓性白血病患者的长期疗效。
Leukemia. 2015 Sep;29(9):1823-31. doi: 10.1038/leu.2015.152. Epub 2015 Jun 19.
9
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.合并症对慢性髓性白血病患者总生存的影响:随机CML研究IV的结果
Blood. 2015 Jul 2;126(1):42-9. doi: 10.1182/blood-2015-01-617993. Epub 2015 Apr 27.
10
Kaplan-Meier Survival Analysis Overestimates the Risk of Revision Arthroplasty: A Meta-analysis.卡普兰-迈耶生存分析高估了翻修关节成形术的风险:一项荟萃分析。
Clin Orthop Relat Res. 2015 Nov;473(11):3431-42. doi: 10.1007/s11999-015-4235-8.